BACKGROUND AND AIMS: Vedolizumab inhibits leucocyte vascular adhesion and migration into the gastrointestinal tract through a4b7 integrin blockade. This agent became available in mid-2014 for the treatment of moderate to severe @entity30 ( @entity30 ) and UC (UC). The aim of this study was to assess the patterns of use, effectiveness and safety of vedolizumab in an @entity29 ( @entity29 ) clinical practice. METHODS: @entity1 beginning vedolizumab were enrolled with informed consent. A prospective cohort was followed with laboratory, disease activity and quality-of-life assessments made during infusion visits up to week 14. Duration of vedolizumab use, mucosal healing and safety were analysed retrospectively for all @entity1 not captured in the prospective component of this study. RESULTS: One hundred and two @entity1 started vedolizumab, with 51 @entity1 (30 @entity30 , 21 UC) followed prospectively. The @entity30 @entity1 exhibited a significant decrease in @entity30 Activity Index (p = 0.04) and Harvey-Bradshaw index (p < 0.01) by week 14. The UC @entity1 demonstrated improved partial Mayo scores at weeks 6 (p < 0.01) and 14 (p < 0.001). Ninety percent of all @entity30 and UC @entity1 remained on vedolizumab up to week 14. @entity29 -related quality of life was improved by week 6 in @entity30 and UC cohorts (p = 0.02 and p < 0.01 respectively). Colectomy for lack of response and systemic histoplamosis were notable reasons for early discontinuation of vedolizumab, which was otherwise well tolerated. CONCLUSIONS: Vedolizumab was efficacious and a high percentage of @entity1 continued this therapy beyond induction dosing. Observed safety signals may be attributed to the refractory @entity29 disease state of this early-adopting clinical cohort.

Vedolizumab Effectiveness and Safety Over the First Year of Use in an XXXX Clinical Practice.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's Disease", "Crohn's disease"] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']
@entity29 :: (MESH:D015212,Disease) :: ['IBD']
